Cryo-Cell International (CCEL) AI Stock Analysis

• Market Cap: $41.78M
• Dividend Yield: 11.79%
• Average Volume (3M): 9.72K
• Price to Earnings (P/E): 407.2
• Beta (1Y): >-0.01
• Revenue Growth: 2.33%
• EPS Growth: N/A
• Country: US
• Employees: 82
• Sector: Healthcare
• Sector Strength: 59
• Industry: Medical - Care Facilities
• EPS (TTM): 0.01
• Shares Outstanding: 8,082,159
• 10 Day Avg. Volume: 10,007
• 30 Day Avg. Volume: 9,721
• PEG Ratio: 0.50
• Price to Book (P/B): -24.27
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.30
• Enterprise Value/Market Cap: 1.12
• Enterprise Value/Revenue: 0.37
• Enterprise Value/Gross Profit: 1.93
• Enterprise Value/Ebitda: -3.67
• 1Y Price Target: $8.50
• Price Target Upside: 66.99% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 54 Neutral
• Price Target: $5.00 ▼(-1.77%Downside)

Cryo-Cell International's overall stock score is weighed down primarily by high leverage risks and negative corporate events. While financial performance shows some operational improvements, the balance sheet weaknesses and high valuation pose significant concerns. The attractive dividend yield partially offsets these risks.

Positive Factors

Business Model

Cryo-Cell's business model is highly appealing due to its mostly recurring revenues and positive cash flow generation.

Dividend

The company maintains a high dividend yield of 18.1%, which is attractive to investors seeking regular income.

Financial Performance

Cryo-Cell International reported a beat on revenue and EBITDA.

Negative Factors

Financial Estimates

Higher litigation expenses and Duke royalty expenses have led to a reduction in financial estimates.

Litigation

The ongoing arbitration against Duke University could potentially impact the company's financial position, with management believing damages could exceed $100M.

Litigation Expenses

Higher expenses are expected due to litigation costs and Duke royalty expenses being accrued.

Cryo-Cell International Business Overview & Revenue Model

Company Description

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

How the Company Makes Money

Cryo-Cell International primarily generates revenue through the fees it charges for its cryopreservation services. The company collects an initial processing fee when customers enroll in its storage program for umbilical cord blood and tissue. In addition to this upfront charge, Cryo-Cell earns recurring revenue from annual storage fees paid by clients who maintain their stored specimens with the company. These long-term storage contracts contribute significantly to the company's financial stability. Furthermore, Cryo-Cell may also have partnerships with healthcare providers and hospitals that refer clients to its services, enhancing its market reach and customer base.

Cryo-Cell International Financial Statement Overview

Summary

Cryo-Cell International shows steady revenue growth and improved operational efficiency. However, the company faces challenges with high leverage and negative equity, though strong cash flow provides some financial cushioning.

Income Statement

Cryo-Cell International shows steady revenue growth over the years with a recent increase in gross profit margin to 75.80% TTM. However, net profit margin remains thin at 0.40% TTM, indicating limited profitability. EBIT and EBITDA margins improved to 11.57% and 12.42% TTM respectively, reflecting better operational efficiency.

Balance Sheet

The balance sheet highlights a negative stockholders' equity of -$14.66 million TTM, raising concerns about financial stability. The debt-to-equity ratio is not applicable due to negative equity, and the equity ratio is negative, indicating high leverage risks. However, there is a moderate reduction in total debt.

Cash Flow

Operating cash flow is strong at $7.32 million TTM, with a free cash flow to net income ratio of 31.96, indicating good cash generation relative to earnings. Free cash flow growth is positive, supporting future investment opportunities.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
32.10M	31.99M	31.34M	30.34M	28.88M	31.15M
	Gross Profit
24.33M	24.04M	22.90M	21.54M	19.90M	21.49M
	EBIT
3.72M	3.48M	-12.30M	4.02M	4.00M	7.66M
	EBITDA
3.99M	1.42M	-10.42M	6.65M	5.32M	7.22M
	Net Income Common Stockholders
128.71K	402.10K	-9.52M	2.77M	2.08M	3.62M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.48M	3.50M	980.25K	1.72M	8.34M	10.45M
	Total Assets
64.38M	64.68M	61.22M	64.89M	60.66M	46.20M
	Total Debt
13.86M	12.93M	10.90M	11.61M	2.82M	6.24M
	Net Debt
13.64M	12.37M	10.49M	9.91M	-5.44M	-4.12M
	Total Liabilities
79.04M	77.89M	72.25M	66.41M	56.48M	48.87M
	Stockholders Equity
-14.66M	-13.22M	-11.03M	-1.52M	4.18M	-2.67M
Cash Flow		Free Cash Flow
4.11M	3.61M	1.28M	-8.60M	974.92K	8.02M
	Operating Cash Flow
7.32M	6.01M	8.92M	8.57M	7.93M	8.47M
	Investing Cash Flow
-4.82M	-4.88M	-8.14M	-15.28M	-6.95M	357.49K
	Financing Cash Flow
-2.52M	-979.12K	-2.07M	147.86K	-3.07M	-5.00M

Cryo-Cell International Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCEL, the sentiment is Negative. The current price of 5.09 is above the 20-day moving average (MA) of 5.03, below the 50-day MA of 5.16, and below the 200-day MA of 6.38, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 49.24 is Neutral, neither overbought nor oversold. The STOCH value of 52.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCEL.

Cryo-Cell International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	68 Neutral	$433.25M	5.55	-58.97%	―	23.81%	146.45%
CCEL	54 Neutral	$41.78M	407.20	93.38%	11.79%	2.33%	―
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
MBOT		$90.22M	―	-66.48%	―	―	―
KRON	51 Neutral	$54.42M	―	-59.49%	―	21.15%	46.44%
GANX	46 Neutral	$53.90M	―	-290.21%	―	-100.00%	44.28%
STTK	44 Neutral	$48.38M	―	-71.90%	―	69.65%	27.98%

Cryo-Cell International Corporate Events

Cryo-Cell Faces License Termination by Duke University

Cryo-Cell International, Inc. has received a notice of termination from Duke University regarding their Patent and Technology License Agreement, effective May 17, 2025. The termination is based on Duke’s claim that Cryo-Cell breached the agreement, following Cryo-Cell’s arbitration demand alleging fraudulent inducement and multiple breaches by Duke.

The most recent analyst rating on (CCEL) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.

Cryo-Cell International Declares Reduced Quarterly Dividend

On May 7, 2025, Cryo-Cell International‘s Board of Directors declared a reduced quarterly cash dividend of $0.15 per share, reflecting the current economic environment and capital allocation alternatives. This decision, announced on May 8, 2025, may impact shareholder returns and indicates a cautious approach to financial management amid uncertain economic conditions.